BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.
Strong Bullish
92.0